# HRTX catalysts: HERON THERAPEUTICS, INC. /DE/ PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/hrtx/catalysts

> HERON THERAPEUTICS, INC. /DE/ (HRTX) has no upcoming catalysts in this calendar. The latest recorded is the HERON THERAPEUTICS, INC. /DE/ earnings report, November 9, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | HERON THERAPEUTICS, INC. /DE/ |
| Ticker | HRTX (Nasdaq) |
| SEC CIK | 818033 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/hrtx |

## Cash runway

Cash $23.4M as of 2026-09-30; quarterly burn $794K; about 88.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-452759).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 30, 2019 | [ZYNRELEF® (bupivacaine-meloxicam) complete response letter (CRL)](https://sec-api.dev/pdufa/bupivacaine-meloxicam) | HRTX |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22211988_2022_Orig1s000OtherActionLtrs.pdf%22)) |
| June 26, 2020 | [ZYNRELEF® (bupivacaine-meloxicam) complete response letter (CRL)](https://sec-api.dev/pdufa/bupivacaine-meloxicam) | HRTX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22211988_2022_Orig1s000OtherActionLtrs.pdf%22)) |
| Dec 2021 | [ZYNRELEF® (bupivacaine-meloxicam) FDA approval](https://sec-api.dev/pdufa/bupivacaine-meloxicam) | HRTX |  | completed, approved | "In December 2021, the FDA approved an expansion of ZYNRELEF's indication to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-ex99_1.htm)) |
| Sep 2022 | [APONVIE® (aprepitant) FDA approval](https://sec-api.dev/pdufa/aprepitant) | HRTX |  | completed, approved | "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-ex99_1.htm)) |
| March 6, 2023 | [APONVIE® (aprepitant) FDA approval](https://sec-api.dev/pdufa/aprepitant) | HRTX |  | completed, approved | "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-ex99_1.htm)) |
| December 12, 2023 | [CINVANTI® (cinvanti) NDA/BLA submission](https://sec-api.dev/pdufa/cinvanti) | HRTX |  | completed | "On December 12, 2023, the Company received a Notice Letter (the "Slayback Notice") from Slayback Pharma LLC ("Slayback") advising that Slayback had submitted an NDA under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act to the FDA seeking approval to manufacture, use or sell a generic version of CINVANTI in the U.S. ("Slayback's NDA") prior to the" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/818033/000095017024124698/hrtx-20240930.htm)) |
| January 23, 2024 | [ZYNRELEF® (bupivacaine-meloxicam) FDA approval](https://sec-api.dev/pdufa/bupivacaine-meloxicam) | HRTX |  | completed, approved | "On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-ex99_1.htm)) |
| Sep 2024 | [ZYNRELEF® (bupivacaine-meloxicam) FDA approval](https://sec-api.dev/pdufa/bupivacaine-meloxicam) | HRTX |  | completed, approved | "In September 2024, the FDA approved our Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ("VAN"), which will replace the current vented vial spike." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/818033/000095017025028374/hrtx-20241231.htm)) |
| November 12, 2024 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-ex99_1.htm)) |
| February 27, 2025 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/hrtx-ex99_1.htm)) |
| May 6, 2025 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/hrtx-ex99_1.htm)) |
| August 8, 2025 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017025105474/hrtx-ex99_1.htm)) |
| November 4, 2025 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-ex99_1.htm)) |
| February 26, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-ex99_1.htm)) |
| May 11, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-ex99_1.htm)) |
| August 10, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/hrtx-ex99_1.htm)) |
| November 9, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526452721/hrtx-ex99_1.htm)) |

## Drugs

- [APONVIE® (aprepitant)](https://sec-api.dev/pdufa/aprepitant): 
- [ZYNRELEF® (bupivacaine-meloxicam)](https://sec-api.dev/pdufa/bupivacaine-meloxicam): 
- [CINVANTI® (cinvanti)](https://sec-api.dev/pdufa/cinvanti): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/hrtx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HRTX catalysts: HERON THERAPEUTICS, INC. /DE/ PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/hrtx/catalysts

```bibtex
@misc{secapidev_companies_hrtx_catalysts_20261116,
  title        = {HRTX catalysts: HERON THERAPEUTICS, INC. /DE/ PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/hrtx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_hrtx_catalysts_20261116","title":"HRTX catalysts: HERON THERAPEUTICS, INC. /DE/ PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/hrtx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
